Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy

Published:2012-11-13 Issue:11 Volume:7 Page:e49006
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

McGowan Mary P.,Tardif Jean-Claude,Ceska Richard,Burgess Lesley J.,Soran Handrean,Gouni-Berthold Ioanna,Wagener Gilbert,Chasan-Taber Scott

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference31 articles.

1. Familial hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert panel on Familial Hypercholesterolemia;Hypercholesterolemia National Lipid Association Expert panel on Familial;J Clin Lipidol,2011

2. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia;F Civeira;Atherosclerosis,2004

3. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia;HJ Avis;Arterioscler Thromb Vasc Biol,2007

4. Statin treatment in children with familial hypercholesterolemia: the younger, the better;J Rodenburg;Circulation,2007

5. Familial hypercholesterolaemia;AD Marais;Clin Biochem Rev,2004

Cited by 195 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the potential of antisense oligonucleotides: Mechanisms, therapies, and safety insights;Drug Development Research;2024-05-19

2. Cross-Reactive Polyclonal Antibodies Raised Against GalNAc-Conjugated siRNA Recognize Mostly the GalNAc Moiety;The AAPS Journal;2024-04-03

3. Beyond Statins: Novel Lipid-Lowering Agents for Reducing Risk of Atherosclerotic Cardiovascular Disease;Pharmacoepidemiology;2024-03-05

4. Oligonucleotide therapeutics and their chemical modification strategies for clinical applications;Journal of Pharmaceutical Investigation;2024-02-29

5. Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?;Cardiology and Therapy;2024-02-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3